IL17A and leukemia: More strikingly, the combination of anti-IL-17A antibodies and imatinib synergistically decreased leukemia cell infiltration and population in the spleens, PB, BM, and LNs of recipients and significantly enhanced the survival of B-ALL cell-engrafted mice (Fig. 3l-n), suggesting that combination treatment with anti-IL-17A and imatinib increased the therapeutic efficacy of imatinib.